<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01493648</url>
  </required_header>
  <id_info>
    <org_study_id>MOP 114917</org_study_id>
    <nct_id>NCT01493648</nct_id>
  </id_info>
  <brief_title>Muscle-Related Side Effects of Statins: Functional Impact, Mechanisms, and Potential Relief With Vitamin D Supplementation</brief_title>
  <official_title>Muscle-Related Side Effects of Statins: Functional Impact, Mechanisms, and Potential Relief With Vitamin D Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal will explore muscle function (strength and endurance) in men and women
      suffering from statin-induced muscle symptoms. The mechanisms responsible for these muscle
      symptoms will be explored. Also, the investigators will assess the potential usefulness of
      vitamin D supplementation in a randomized control trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Statins are a class of drugs that are widely prescribed to lower blood cholesterol levels.
      Although they have few side effects, many patients report muscle pain, cramps, and weakness
      when using these drugs. We know very little on the real impact of these muscle symptoms on
      patient quality of life, especially in relation to muscle strength and endurance.

      Patients under statin therapy will stop medication for 2 months. Results from blood sample,
      muscle function and muscle biopsy (in some participants) will be compared with baseline.
      Participants will then take vitamin D supplementation or placebo for one month. Thereafter,
      statin will be reintroduced for two months while continuing vitamin D or placebo
      supplementation. At the end of that time, measures from blood sample, muscle function and
      muscle biopsy will be compared with other visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain score</measure>
    <time_frame>Change from baseline at 2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in muscle function testing</measure>
    <time_frame>Change from baseline at 2 months</time_frame>
    <description>Strenght and endurance evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in muscle histology</measure>
    <time_frame>Change from baseline at 2 months</time_frame>
    <description>Histological, ultrastructural and metabolic assessment of muscle biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain score</measure>
    <time_frame>Change from baseline at 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle function testing</measure>
    <time_frame>Change from baseline at 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle histology</measure>
    <time_frame>Change from baseline at 5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>HMG COA Reductase Inhibitor Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>Cholecalciferol, D-tabs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo (lactose 100 mg) for 3 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  statin therapy

          -  healthy and sedentary or moderately physical active

        Exclusion Criteria:

          -  Current treatment with other lipid-lowering drugs

          -  Natural medicine affecting lipid metabolism

          -  CK levels above the normal range

          -  Clinical vitamin D deficiency

          -  Impaired liver or kidney function

          -  Untreated hypo- or hyperthyroidism

          -  Treatment with other medications known to increase risk of myopathy

          -  Existing infection requiring antibiotic therapy

          -  Consumption of greater than 60 ml of grapefruit juice per day

          -  Inherited muscle disorders or myopathy

          -  Polymyositis or inflammatory myopathy

          -  Use of corticosteroids

          -  Comorbidities resulting in muscle or bone pain

          -  History of elevated CK

          -  Unexplained cramps

          -  Known sickle cell trait

          -  Cancer within the 5 years prior to study entry

          -  Diabetes

          -  Stroke, coronary artery or peripheral vascular disease

          -  Physical disability or previous injury interfering with exercise testing

          -  Pregnant or breastfeeding

          -  Depression (in last 3 years) or treatment with antidepressants

          -  Use of anti-psychotic drugs

          -  Alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis R Joanisse, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Bergeron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Quebec-Universite Laval</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jérôme Frenette, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Quebec-Universite Laval</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Québec - CHUL</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2011</study_first_submitted>
  <study_first_submitted_qc>December 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2011</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>statins</keyword>
  <keyword>side effects</keyword>
  <keyword>muscle</keyword>
  <keyword>vitamin D</keyword>
  <keyword>biopsy</keyword>
  <keyword>strength</keyword>
  <keyword>fatigue</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

